Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

This study has been terminated.
(Problems with IRB)
Sponsor:
Collaborators:
Milton S. Hershey Medical Center
Information provided by (Responsible Party):
Jill P. Smith, Penn State University
ClinicalTrials.gov Identifier:
NCT00783172
First received: October 30, 2008
Last updated: February 11, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2011
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)